Protalix Q3 revenues from goods up 16% to $10.2M; net loss narrows to $1.9M

Protalix BioTherapeutics, Inc.

2023-Q3 EPS reported $0.16 revenue$55,008,000

Revenues from selling goods $10.2M (+16% YoY), driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
License and R&D service revenues fell 96% to $0.2M as extension studies transferred to Chiesi.
Net loss improved to $1.9M ($0.03 basic EPS) vs $3.6M loss ($0.07 EPS) in Q3 2022.
Cash and equivalents $41.0M; PRX-115 Phase I for gout enrolled 32 patients, results expected mid-2024.
Regulatory: UK MHRA and Swissmedic approved Elfabrio; Dr. Eliot Forster appointed Board Chairman.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017657

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.